2021
DOI: 10.1016/j.jns.2021.117552
|View full text |Cite
|
Sign up to set email alerts
|

Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(10 citation statements)
references
References 37 publications
0
10
0
Order By: Relevance
“…Limited (up to 2 years) observation periods, 28,29 mixed patient's cohorts, 29-31 or lack of validation of the degree of chronic demyelination 29-31 may explain why some of the previously reported studies failed to detect accelerated axonal loss in the eyes of patients with RRMS with a history of ON. The most recent study, 32 which followed mixed cohort of patients with MS for 5 years, showed a significant relationship between RNFL thinning and previous history of ON only in the progressive, but not in patients with relapsing-remitting MS. However, contrary to patients with progressive MS, the baseline degree of optic nerve damage caused by acute ON (and, therefore, degree of chronic demyelination) in ON eyes of patients with RRMS was minimal, if any.…”
Section: Discussionmentioning
confidence: 99%
“…Limited (up to 2 years) observation periods, 28,29 mixed patient's cohorts, 29-31 or lack of validation of the degree of chronic demyelination 29-31 may explain why some of the previously reported studies failed to detect accelerated axonal loss in the eyes of patients with RRMS with a history of ON. The most recent study, 32 which followed mixed cohort of patients with MS for 5 years, showed a significant relationship between RNFL thinning and previous history of ON only in the progressive, but not in patients with relapsing-remitting MS. However, contrary to patients with progressive MS, the baseline degree of optic nerve damage caused by acute ON (and, therefore, degree of chronic demyelination) in ON eyes of patients with RRMS was minimal, if any.…”
Section: Discussionmentioning
confidence: 99%
“…At partial 2 (η2) values, 0.01 is considered low potency, 0.06 is considered average potency, and 0.14 and above is considered high potency (Jakimovski et al, 2021 ). According to the partial effect size value, an average effect in the interval test and a high potential effect in the post-test results were detected in favour of the DGBLL (η2 (interval test) = 0.09; η2 (post-test) = 0.50).…”
Section: Resultsmentioning
confidence: 99%
“…Disease progression without a relapse, typical for primary progressive (PPMS) or secondary progressive MS (SPMS), is also associated with increased GCIPL and pRNFL thickness loss [40]. This could, to a certain extent, explain why progressive MS patients show faster annual pRNFL and GCIPL thinning and lower values at baseline compared to RRMS [28, [41][42][43]. As mentioned before, GCIPL and pRNFL can be correlated with brain atrophy and spinal cord atrophy, cortical lesion volume, and leptomeningeal enhancement [44][45][46][47][48].…”
Section: Long-term Oct Changes In Ms Patientsmentioning
confidence: 99%
“…From the group of highly effective disease-modifying therapies, natalizumab showed a significantly reduced pRNFL thinning compared to first-line injectables [ 42 ]. While alemtuzumab exhibited stable RNFL and GCIPL parameters, proving a certain neuroprotective effect, rituximab showed increased GCIPL atrophy rates during the first 12 months of treatment but subsequently decreased atrophy rates similar to healthy controls in a study with a small case number [ 77 ].…”
Section: Optical Coherence Tomographymentioning
confidence: 99%